Dec 15, 2010
Lundbeck Embarks on Research Initiative to Identify and Develop Therapies that May Slow or Halt the Progression of Huntington’s Disease
Lundbeck Inc. today launched a Huntington’s disease (HD) research initiative to identify and ultimately commercialize therapies that may slow or halt the progression of the disease. The research will be driven by collaborations with academic institutions and companies with promising compounds in development.
Dec 04, 2010
Lundbeck Reports Positive Phase III Study Results for Clobazam in the Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome
Lundbeck Inc. presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome (LGS).
Sep 10, 2010
Lundbeck wins Federal Trade Commission case in Federal District Court
U.S. Federal District Court rules in favour of Lundbeck and found no violation of the antitrust laws in the Company’s acquisition of NeoProfen® (ibuprofen lysine) Injection (10mg/mL), a drug used in premature infants with patent ductus arteriosus (PDA), a condition in which a blood vessel in the heart fails to close after birth.